BARCHIESI, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 6.198
EU - Europa 3.060
AS - Asia 1.374
AF - Africa 68
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
Totale 10.720
Nazione #
US - Stati Uniti d'America 6.176
UA - Ucraina 769
IE - Irlanda 457
TR - Turchia 429
IT - Italia 387
SG - Singapore 377
SE - Svezia 369
DE - Germania 330
DK - Danimarca 283
CN - Cina 220
FI - Finlandia 168
KR - Corea 152
GB - Regno Unito 137
HK - Hong Kong 136
FR - Francia 115
CI - Costa d'Avorio 61
IN - India 24
IR - Iran 24
CA - Canada 19
BE - Belgio 14
BR - Brasile 9
BA - Bosnia-Erzegovina 6
EU - Europa 6
AT - Austria 5
MA - Marocco 4
NL - Olanda 4
MX - Messico 3
RU - Federazione Russa 3
AU - Australia 2
CM - Camerun 2
ID - Indonesia 2
KG - Kirghizistan 2
MD - Moldavia 2
PL - Polonia 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
ES - Italia 1
IL - Israele 1
JP - Giappone 1
KH - Cambogia 1
KZ - Kazakistan 1
LT - Lituania 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
TW - Taiwan 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 10.720
Città #
Jacksonville 794
Fairfield 742
Chandler 537
Dublin 452
Boardman 422
Ashburn 357
Wilmington 313
Woodbridge 303
Seattle 252
Houston 245
Des Moines 242
Cambridge 241
New York 208
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Singapore 164
Hong Kong 132
Turin 103
San Diego 97
Abidjan 61
Centro 51
Redmond 41
Beijing 32
London 24
Shanghai 23
Helsinki 21
Los Angeles 18
Norwalk 18
Washington 18
Marche 16
Ottawa 16
Brussels 14
Guangzhou 14
Ancona 13
Kilburn 13
Pune 12
Wuhan 12
Dallas 10
Bologna 9
Izmir 8
Milan 8
Bari 7
Nuremberg 7
San Severino Marche 7
Falls Church 6
Ferrara 6
Sarajevo 6
Andover 5
Jiaxing 5
Prescot 5
Wuxi 5
Acton 4
Auburn Hills 4
Chiswick 4
Falconara Marittima 4
Hanover 4
Jinhua 4
Paris 4
Pesaro 4
Rome 4
Seoul 4
Shenzhen 4
Appignano 3
Cingoli 3
Delhi 3
Heze 3
Hounslow 3
Islington 3
Macerata 3
Mountain View 3
Nanjing 3
Naples 3
Porto 3
Squinzano 3
Yiwu 3
Amsterdam 2
Arco 2
Bhopal 2
Bishkek 2
Cava De' Tirreni 2
Central 2
Chengdu 2
Conegliano 2
Copenhagen 2
Corridonia 2
Fayetteville 2
Indore 2
Monterrey 2
Montesilvano Marina 2
Napoli 2
New Bedfont 2
Olgiate Comasco 2
Osimo 2
Palermo 2
Quanzhou 2
Rimini 2
Santa Clara 2
Tiantai Chengguanzhen 2
Totale 6.955
Nome #
Antimicrobial Resistance: A Challenge for the Future 165
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 116
Candida guilliermondii fungemia in patients with hematologic malignancies. 111
Trichosporon beigelii fungaemia in an AIDS patient. 108
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 107
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 104
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 101
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 100
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 98
Antimicrobial activity of polycationic peptides 97
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 96
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 94
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 92
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 92
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 91
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 91
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 91
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 90
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 90
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 90
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 90
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 86
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 86
Epidemiology and microbiology of surgical wound infections. 85
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 85
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 84
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 83
Characterisation of candidemia in patients with recent surgery: A 7-year experience 83
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 82
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 82
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 82
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 82
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 81
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 81
Candidemia in the elderly: What does it change? 81
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 78
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 78
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 77
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 77
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 75
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 74
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 73
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 73
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 71
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 70
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 70
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 70
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 70
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 70
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 69
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 68
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 66
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 66
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 66
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 66
null 66
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 65
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. 65
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 65
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 65
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 65
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 65
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 64
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 64
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 64
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 64
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 64
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 64
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 63
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 63
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 63
EUCAST Technical Note on voriconazole. 63
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 63
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 62
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 62
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 62
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence. 61
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 61
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 60
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 60
EUCAST technical note on posaconazole. 60
Posaconazole prophylaxis in experimental systemic zygomycosis. 59
Caspofungin in combination with amphotericin B against Candida glabrata. 59
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 58
Caspofungin in combination with amphotericin B against Candida parapsilosis. 58
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 58
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 58
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. 58
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 57
Inhibition of growth of Pneumocystis carinii by lactoferrins singly and in combination with pyrimethamine, clarithromycin and minocycline. 56
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 56
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 56
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 56
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 56
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 56
Efficacy of caspofungin against Aspergillus terreus 56
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 56
Voriconazole and multidrug resistance in Candida albicans. 55
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. 55
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746. 55
Totale 7.425
Categoria #
all - tutte 66.964
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.964


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020532 0 0 0 0 0 0 0 8 170 81 34 239
2020/20212.631 148 273 353 48 304 190 253 159 223 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.299 214 25 68 240 248 280 26 18 15 15 15 135
2024/2025941 222 207 166 29 65 61 172 19 0 0 0 0
Totale 10.929